36 citations
,
May 2005 in “BMC dermatology” This study found that topical diphenylcyclopropenone was effective in treating severe alopecia areata but had a high relapse rate and was often accompanied by side effects like eczema and lymphadenopathy.
45 citations
,
January 2010 in “International journal of trichology” This review examines topical immunotherapy for severe alopecia areata, noting that diphencyprone and squaric acid dibutylester are non-mutagenic options with similar efficacy but different practical considerations, and reports no new clinical results.
1 citations
,
August 2024 in “Skin Health and Disease” Among pediatric alopecia areata patients treated with DPCP, this study reported complete hair regrowth in 8.8% and any regrowth in 61.8% after one year, with better outcomes for those with milder initial symptoms and longer treatment durations.
1 citations
,
December 2017 in “Dermatology - Open Journal” This case study reports successful regression of alopecia areata in a female patient through DPCP immunotherapy supported by oral antihistamines and topical corticosteroids, suggesting indirect antihistamine effects on allergic inflammation may contribute to improvement.
January 2024 in “Annals of Dermatology” This study found that DPCP immunotherapy effectively treats alopecia areata, identifying factors that influence treatment response and patient satisfaction, which may aid in standardizing the treatment for improved outcomes.